Clinical outcome of varying doses of Micropulse Trans-Scleral Photocoagulation (MP-TSCPC) laser in patients with glaucoma
This study enrolls adults with Glaucoma who are scheduled for surgery. The purpose of this study is to learn the effects of varying the dose of the laser in a certain glaucoma surgical procedure (called MicroPulse Trans-Scleral CycloPhotoCoagulation).
You will be in this study for 2-3 years. The study is conducted as a part of your routine post-surgical clinic visits, so we don't anticipate there being any extra visits or extra costs. Your surgery and prepost-surgical care will be given the same as if you were not in the study. The only difference is that you will be randomly assigned (like the flip of a coin) a certain laser dosage. This study takes place at the Ross Eye Institute/UBMD Ophthalmology in Buffalo, NY.
Compensation is not available.
This is a prospective study to evaluate the clinical outcome of varying doses of Micropulse Trans-Scleral Photocoagulation (MP-TSCPC) laser in patients with glaucoma. The study will assess documented complication rates, changes in visual acuity after the procedure, changes in intraocular pressures and medication drop usage, and need for subsequent treatments (including further laser or surgery).
-Adults ages 18+ who have been diagnosed with Glaucoma.
-People who have been invited to participate because they have been scheduled for MicroPulse Trans-Scleral CycloPhotoCoagulation (MP-TSCPC) surgery
Due to COVID-19, new enrollment in research studies will be greatly limited.
If you are interested in a study, there may be a longer waiting period to receive a response to your inquiry.
View the guidance for research participants for additional information.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email firstname.lastname@example.org and someone will assist you.